Arbutus Biopharma Corporation

DB:I9DN Stock Report

Market Cap: €459.8m

Arbutus Biopharma Management

Management criteria checks 2/4

Arbutus Biopharma's CEO is Mike McElhaugh, appointed in Nov 2022, has a tenure of 1.42 years. total yearly compensation is $1.62M, comprised of 29.8% salary and 70.2% bonuses, including company stock and options. directly owns 0.74% of the company’s shares, worth €3.38M. The average tenure of the management team and the board of directors is 2.6 years and 5.5 years respectively.

Key information

Mike McElhaugh

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage29.8%
CEO tenure1.4yrs
CEO ownership0.7%
Management average tenure2.6yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mike McElhaugh's remuneration changed compared to Arbutus Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$483k

-US$73m

Sep 30 2023n/an/a

-US$75m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$1mUS$449k

-US$69m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021n/an/a

-US$88m

Sep 30 2021n/an/a

-US$87m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$79m

Dec 31 2020US$1mUS$415k

-US$76m

Compensation vs Market: Mike's total compensation ($USD1.62M) is above average for companies of similar size in the German market ($USD1.02M).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.


CEO

Mike McElhaugh (48 yo)

1.4yrs

Tenure

US$1,620,485

Compensation

Mr. Michael J. McElhaugh, also known as Mike, co-founded Arbutus Biopharma Inc. in 2012 and serves as its Interim President and Chief Executive Officer and Director since January 1, 2024. Mr. McElhaugh had...


Leadership Team

NamePositionTenureCompensationOwnership
Michael McElhaugh
Co-Founder1.4yrsUS$1.62m0.74%
$ 3.4m
Michael Sofia
Chief Scientific Officer9.3yrsUS$1.61m0.83%
$ 3.8m
David Hastings
CFO & Chief Accounting Officer5.8yrsUS$1.46m0.0093%
$ 42.7k
Lisa Caperelli
Vice President of Investor Relations2.6yrsno datano data
J. Naftzger
General Counselless than a yearno datano data
Shannon Briscoe
Vice President of Human Resourcesno datano datano data
Karen Sims
Chief Medical Officerless than a yearno data0.0029%
$ 13.5k
R. Mackay-Dunn
Corporate Secretary13.9yrsno datano data

2.6yrs

Average Tenure

59yo

Average Age

Experienced Management: I9DN's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael McElhaugh
Co-Founderless than a yearUS$1.62m0.74%
$ 3.4m
Richard Henriques
Independent Non-Executive Director9.3yrsUS$136.42k0.00056%
$ 2.6k
Daniel Burgess
Independent Director7.1yrsUS$161.74k0%
$ 0
Keith Manchester
Independent Non-Executive Director9.1yrsUS$156.74k0%
$ 0
Adrian Di Bisceglie
Member of Scientific Advisory Boardno datano datano data
Charles Rice
Member of Scientific Advisory Boardno datano datano data
James Meyers
Independent Director5.5yrsUS$176.74k0%
$ 0
William Symonds
Chairman of Scientific Advisory Board5.5yrsno data0%
$ 0
Frank Torti
Independent Chairman of the Board of Directors5.4yrsUS$187.99k0%
$ 0
Fabien Zoulim
Member of Scientific Advisory Boardno datano datano data
Scott Biller
Member of Scientific Advisory Boardno datano datano data
Ulrike Protzer
Member of Scientific Advisory Boardno datano datano data

5.5yrs

Average Tenure

56.5yo

Average Age

Experienced Board: I9DN's board of directors are considered experienced (5.5 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.